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MATERIAL and METHODS 
Material and instruments 
HSA (25% solution) and doxorubicin hydrochloride were purchased from Octapharma USA 
and Synbias Pharm, respectively. Methanol, ethanol, Spectrum dialysis membranes (12-14 kD 
MWCO), and Zeba desalting spin columns were from VWR. Doxorubicin UV spectrum 
measurement and quantitation were conducted on a UV-1600 PC spectrometer (VWR). A FRET 
master fluorometer (Photon Technology International) was used to measure fluorescence. Particle 
size distributions were determined by a Zetasizer Nano dynamic light scattering system (Malvern 
Panalytical). DOX-HSA mixtures were prepared by adding the desired amount of aqueous DOX 
solution and HSA solution into PBS buffer to form DOX-HAS mixtures with the desired ratios of 
DOX to HSA. 
 
Preparation of SPEDOX complexes and their analysis 
DOX quantitation was based on its strong absorbance between 450-550 nm. Linear standard 
calibration curves were used to calculate DOX’s molar extinction coefficients (εnm) under different 
conditions – ε481 = 11,500 cm
-1
 M
-1
 and ε547 = 3,900 cm
-1
 M
-1 
in PBS buffer, ε481 = 11,800 cm
-1
 M
-1
 
in acetate buffer. For SPEDOX in PBS, ε547 = 3,900 cm
-1
 M
-1
. 
All SPEDOX complexes were prepared according to the following general procedure 
described briefly. To a 50 mL round flask equipped with a magnetic stir bar, were added 4.0 mL of 
25 % HSA solution (1.0 g of HSA), 2.0 mL of deionized water, 1.0 mL of 50% methanol-water 
 
  
mixture, and 1.0 mL of 56% ethanol-water mixture. The resulting mixture was stirred for 5 minutes 
at room temperature. Separately, 27 mg to 80 mg of doxorubicin hydrochloride (the pre-determined 
DOX/HSA ratios)  was mixed with 4.0 mL of deionized water in a 15 mL centrifuge tube. Different 
amounts of DOX were used to produce SPEDOX complexes containing different [DOX]/[HSA] 
ratios ranging from 3 to 9. The mixture was vortexed thoroughly until all solid was dissolved to 
form a red solution, which was then added into the above HSA solution while stirring, followed by 
adding 1.0 mL of 56% ethanol-water mixture. Subsequently, the pH was brought up to 11.0 by 
using 1.0 M NaOH solution. The mixture was continuously stirred for specific times (from 7 to 12.6 
hours) to achieve the desired binding strength between DOX and HSA. The encapsulation process 
was conveniently monitored by UV absorbance analysis of samples taken at different time intervals 
and diluted in PBS. The A547/A481 ratio was then calculated and used as a reliable indicator for 
DOX encapsulation strength. Free DOX has maximum absorbance at 481 nm. The absorbance at 
the isosbestic point of 547 nm remained unchanged during the encapsulation process, thereby 
providing a constant reference point for ratio calculation. Once the desired binding strength was 
achieved, the mixture was concentrated by a high vacuum pump to remove most of the organic 
solvents. After adjusting the pH to 7.4, the resulting red solution was filtered through a 0.2 µm 
polyethersulfone membrane. The concentration of DOX in SPEDOX complexes was determined by 
UV absorbance in PBS using ε547 and [DOX]/[HSA] ratio was re-calculated. Finally, 20 mL of the 
solution containing a known amount of SPEDOX were aliquoted into 50 mL tubes and lyophilized 
to yield red powdered products. A series of SPEDOX complexes with different DOX loading 
(SPEDOX-1, SPEDOX-2, and SPEDOX-3 with DOX/HSA ratios = 4.0, 7.0, 9.0, respectively, and 
a constant A547/A481 ratio = 0.54) and binding strength (SPEDOX-4, SPEDOX-5, SPEDOX-6 and 
 
  
SPEDOX-7 with A547/A481 ratios = 0.46, 0.49, 0.53, 0.56, respectively, and a constant DOX/HSA 
ratio = 9.0) were successfully prepared.  
Fluorescence analysis was conducted with the excitation at 470 nm and emission spectra 
from 510-700 nm were recorded. For potassium iodide (KI) quenching experiments, different 
amounts of KI were added to s defined concentration of DOX, DOX-HSA mixture, or SPEDOX-6 
to collect fluorescence spectra, F510 was used to calculate fluorescence quenching.  
 
Dialysis  
Membrane dialysis kinetics were examined to evaluate the relative DOX encapsulation 
strength and DOX release from SPEDOX complexes under two different pH conditions. A series of 
powdered samples containing 5.0 mg of DOX or DOX equivalent from SPEDOX-1 to SPEDOX-7 
were each dissolved in 6.0 mL of PBS buffer (pH = 7.4) or acetate buffer (pH = 5.2) and the 
resulting clear red solutions were transferred into separate dialysis bags. Each dialysis bag was then 
placed into a jar containing 350 mL of PBS buffer that was previously degassed by nitrogen for 30 
minutes. The jars were capped airtight and placed in a dark room to avoid UV radiation. At 
different time intervals, 2.0 mL of the buffer solutions in the jars were taken out and analyzed by 
UV spectrometry to determine the total amount of dialyzed-out free DOX, which was calculated 
using A481 and ε481. A separate series of dialysis studies were conducted in acetate buffer (pH 5.2) 
following the same procedure. Each dialysis study was conducted in triplicate. 
 
 
 
 
 
  
In Vivo Study 
All in vivo evaluations of SPEDOX complexes using mice were conducted at Charles River 
Laboratory in accordance with the approval of the Charles River Laboratory Institutional Animal 
Care and Use Committee. 
 
PK studies in mice 
Three female BALB/c mice per group were used for PK studies. A single dose of SPEDOX-
6 at 12 mg/kg DOX equivalent was injected intravenously (IV) into each mouse. Blood samples 
were collected into EDTA-containing tubes at 5 min, 2 h, 4 h, and 24 h. Each sample was then 
equally split into two halves, resulting in two sets of blood samples. The samples from one set were 
passed through desalting spin columns to remove free DOX. Subsequently, both sets of the samples 
were treated with acidic acetonitrile to extract DOX, which was then quantitated by HPLC/MS 
analysis.  The measured difference in DOX amount between the two sets of samples reflected the 
amount of DOX removed by desalting spin columns, and thus represented the amount of free DOX 
in blood samples. 
 
Mouse heart tissue studies  
    
Three female BALB/c mice per group and a single dose (IV) of SPEDOX-6 at 12 mg/kg 
DOX equivalent were used for this study. At 2 h and 24 h post IV injections, animals were 
sacrificed and heart tissues were harvested, weighed, and homogenized. Total DOX was extracted 
and quantitated by the same method as described above.  
 
Evaluation of anti-tumor activity in vivo  
MDA-MB-231 cell line-derived human breast tumor xenografts were produced in eight-
 
  
week old female athymic nude mice according to established methods. When tumor size reached 
80-120 mm
3
, designated as Day 1 of the treatment, mice were sorted into three treatment groups – 
vehicle, DOX, and SPEDOX-6  (n = 8 per group) .
 
In the first antitumor efficacy study, the dosing 
schedule consisted of weekly IV injections for three cycles at a dose of 5 mg/kg free DOX, the 
maximum tolerated dose (MTD), or 10 mg/kg  DOX equivalent SPEDOX-6 (2X of DOX’s MTD). 
Both tumor volume and body weight were measured twice per week. The study endpoint was 
defined as a mean tumor volume of 2000 mm
3
 in the vehicle group (saline only) or 20 days of 
treatment. Based on the results from this study, we conducted the second antitumor efficacy study, 
in which the doses of SPEDOX-6 were increased to 20 mg/kg and 30 mg/kg  DOX equivalent (4X 
and 6X of DOX’s MTD) with an endpoint of tumor volume reaching 2000 mm
3
 or 29 days in the 
vehicle group (n = 4). 
 
Statistical analyses   
For in vitro studies, two-tailed statistical analyses were conducted. Prism summarizes test 
results as not significant (ns) at P > 0.05, significant “*” at 0.01 < P < 0.05, “**” at 0.001 < P < 
0.01, and “***” at P < 0.001. 
To evaluate the inhibitory effects of DOX (5 mg/kg) and SPEDOX-6 (10 mg/kg DOX 
equivalent) on MDA-MB-231 xenograft tumor growth, summary statistics of mean, standard 
deviation, median, and range were calculated for tumor volume changes and proportion of body 
weight changes over time from day 1 for the three groups (vehicle, DOX and SPEDOX-6) of eight 
mice. Data from day 1 were subtracted from values at a specific day for each mouse to calculate 
changes from day 1. These changes were divided by day 1 values to get the proportion changes. 
Same preprocessing was done in the study of the anti-tumor effects of 20 mg/kg and 30 mg/kg 
 
  
DOX equivalent SPEDOX-6 in comparison with the vehicle treatment (four mice per group). 
Linear mixed model regression was done with tumor volume changes and proportion of body 
weight change as the outcomes in two models. Group and day effects were in the model with an 
interaction between group and day. A repeated effect for the animal was used to estimate 
correlation within mouse over time and an unstructured covariance structure was used because the 
variance was not constant over time. Post-hoc pair-wise comparisons for the primary outcome of 
tumor volume changes were made between groups at each time point at each specific day after day 
1 with a Benjamini-Hochberg multiple comparisons procedure applied. A Tukey-Kramer 
adjustment was made for proportion of body weight changes for all pair-wise comparisons. A 
significance level of 0.05 was used for all tests. All statistical analyses were done using SAS 9.4 
(SAS Institute, Cary, NC). 
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Figure S1: A linear relationship between A547/A481 ratio change vs. encapsulation time. 
 
 
Figure S2:  Stern-Volmer (S-V) plots of fluorescence quenching of DOX, DOX-HSA 
mixture, and SPEDOX by KI (potassium iodide): ■ - free DOX (170 nM), ● - DOX-HSA 
mixture ([DOX] = 130 nM + [HSA]= 15 nM),  ▲ - SPEDOX-6 ([DOX]=500 nM and [HSA] = 
56 nM).  
 
   
 
  
 
Figure S3:  DOX docking onto HSA using UCSF Chimera 
(https://www.cgl.ucsf.edu/chimera/) and AutoDock Vina (http://vina.scripps.edu/). HSA and 
DOX structures were derived from PDB ID# 1E78 and 4ZVM, respectively. A) Top 10 DOX 
molecules docked at non-overlapping locations within HSA are shown. The DOX-HSA binding 
Gibbs free energy (ΔG
o
) at the 10 docking sites was calculated to be -9.1, -8.7, -8.6, -8.0, -7.3, -
7.2, -7.2, -7,1, -7.0, and -6.5 kcal/mol, corresponding to Kd values of 0.2, 0.5, 0.5, 1.0, 2.0, 5.0, 
6.0, 7.0, 8.0 and 18.0 µM. The docking generated PDB file is supplied as a separate SI file 
named HSA-DOX complex.pdb.  B) The relative locations of the 10 docked DOX molecules 
after HSA removal from the structure. C) The binding site for DOX1 (ΔG
o
 = -9.1 kcal/mol). D) 
The binding site for DOX9 (ΔG
o
 = -7.0 kcal/mol). 
 
 
  
 
 
 
 
 
Table S1:  Comparison of PK Parameters between SPEDOX-6 and DOX*  
PK parameters 
SPEDOX-6 DOX  
Initial Phase t1/2 (h) 0.426 0.069 
Terminal Phase t1/2 (h) 6.2 11 
AUC (h*ug/mL) 82.54 1.74 
Cmax (ug/mL) 65.9 13 
tmax (h) 0.083 0.083 
 *At 12 mg/kg DOX or DOX equivalent IV injection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
*At 12 mg/kg DOX or DOX equivalent IV injection  
‡
Protein recovery from Zeba desalting spin columns ranged from 70 to 90% according to the 
manufacturer’s protocol. A 70% protein recovery rate was used for correction of % encapsulated 
DOX. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S2:  Encapsulated DOX by SPEDOX-6 in Blood Samples* 
Time (h) 
Total DOX 
(ug/mL) 
Encapsulated  
DOX (ug/mL) 
Encapsulated  
DOX (%) 
Encapsulated DOX  
after Correction (%)
‡
 
0.0833 65.90 34.50 52.3% 74.7% 
2 2.91 1.68 57.7% 82.5% 
8 0.70 0.42 60.0% 85.7% 
24 0.15 0.08 54.7% 78.1% 
 
  
 
*Data were obtained from GEPAI (Gene Expression Profiling Interactive Analysis) 
http://gepia.cancer-pku.cn/.  
 
 
Table S3:  Tumor Types Targeted for SPEDOX Treatment                                                 
(normal/tumor tissue FcRn ratio > 1.6)* 
Tumor Abbr. Tumor Type FcRn ratio 
ACC Adrenocortical carcinoma 2.63 
BLCA Bladder urothelial carcinoma 1.81 
BRCA Breast invasive carcinoma 1.66 
CESC 
Cervical squamous cell carcinoma and endocervical 
adenocarcinoma 
3.48 
CHOL Cholangiocarcinoma 1.75 
DLBC Lymphoid neoplasm diffuse large B- lymphoma 1.55 
KICH Kidney chromophobe 1.92 
LUAD Lung adenocarcinoma 1.62 
LUSC Lung squamous cell carcinoma 3.14 
OV Ovarian serous cystadenocarcinoma 2.30 
PRAD Prostate adenocarcinoma 1.64 
UCEC Uterine corpus endometrial carcinoma 1.61 
